Best Peptides for Growth Hormone Release

Evidence level: Peer reviewed (Phase 3)

Regulatory status: FDA-approved (Egrifta for HIV-associated lipodystrophy)

Tesamorelin (brand name Egrifta) is a stabilized growth hormone-releasing hormone (GHRH) analog that received FDA approval in 2010 for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy — the only GHRH/GHS-class peptide with FDA approval. The pivotal Phase 3 trial, published in the New England Journal of Medicine (Falutz et al., 2010; PMID 20879920), demonstrated significant reduction in visceral adipose tissue (VAT) over 26 weeks in HIV patients with lipodystrophy. Its mechanism involves stimulating endogenous GH release, which in turn increases lipolysis and reduces visceral fat accumulation. The FDA-approved indication is specific to HIV-associated lipodystrophy; online communities discuss tesamorelin for off-label fat loss in non-HIV populations, which is outside the approved indication.

Evidence level: Peer reviewed (legacy clinical literature)

Regulatory status: Previously FDA-approved (Geref, discontinued by manufacturer) — now compounded off-label

Sermorelin is a synthetic N-terminal fragment (1-29) of growth hormone-releasing hormone (GHRH) that was formerly FDA-approved as Geref for diagnostic use in evaluating growth hormone deficiency in children. The manufacturer (EMD Serono) discontinued Geref; the FDA-approved product is no longer commercially available, though the drug was not formally withdrawn for safety reasons. Published clinical literature for sermorelin is primarily from the 1990s–2000s era and focuses on pediatric GH deficiency diagnostic testing; modern adult off-label use via compounding pharmacies lacks robust clinical trial data. Sermorelin is now widely prescribed by telehealth and anti-aging clinics via compounding pharmacies for off-label adult use, which is subject to FDA oversight and the bulk substance risk list framework.

Evidence level: Peer reviewed (Phase 2)

Regulatory status: Not FDA-approved — research use only, development discontinued by Merck

MK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue developed by Merck that mimics ghrelin to stimulate GH and IGF-1 release. Multiple Phase 2 trials published in peer-reviewed journals demonstrated sustained increases in IGF-1 levels. A study published in the Journal of Clinical Endocrinology & Metabolism (Svensson et al., 2000; PMID 10674575) showed that oral MK-677 replicated the pulsatile GH profile seen with intravenous GH secretagogues in healthy older adults. A 12-month Phase 2 study in hip fracture recovery (Bach et al., 2002; PMID 12004295) showed MK-677 improved functional status in elderly patients with hip fracture. Despite positive pharmacodynamic data, Merck did not advance MK-677 to FDA approval. MK-677 is widely sold online as a 'research chemical' or mislabeled as a 'SARM' despite not being a SARM, and FDA warning letters have addressed such marketing.

Evidence level: Peer reviewed (pharmacokinetic study only)

Regulatory status: Not FDA-approved — research use only, development discontinued by ConjuChem

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog developed by ConjuChem Biotechnologies using drug affinity complex (DAC) technology to bind albumin and extend half-life from minutes to days. A published pharmacokinetic/pharmacodynamic study (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism; PMID 16569233) showed that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose — this is the primary peer-reviewed human data. ConjuChem discontinued clinical development and the compound was never submitted to FDA for approval. Two forms exist in community discussions: CJC-1295 with DAC (extended half-life) and CJC-1295 without DAC (modification GRF 1-29); both are research-use-only. CJC-1295 is commonly stacked with ipamorelin in online protocols based on the theoretical rationale of combining GHRH and GHS pathways, but this combination has no FDA-approved clinical data.

Evidence level: Peer reviewed (preclinical pharmacology, limited human data)

Regulatory status: Not FDA-approved — research use only

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that stimulates GH release via ghrelin receptor agonism. The original pharmacology was published in the European Journal of Endocrinology (Raun et al., 1998; PMID 9860070), describing ipamorelin as a selective GHS with minimal cortisol and prolactin release in animal models. It is not FDA-approved for any indication, and human clinical trial data in peer-reviewed literature is extremely limited compared to other GHS compounds like MK-677 or tesamorelin. Online fitness and anti-aging communities frequently describe ipamorelin as the 'safest GHS' based on preclinical selectivity data — this framing reflects community interpretation, not regulatory endorsement. Ipamorelin is commonly stacked with CJC-1295 in telehealth and research-chemical contexts; neither compound is FDA-approved individually or in combination.